Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) have emerged as pivotal treatment modalities for various intracranial lesions, offering precise, non-invasive alternatives to traditional surgery. Over the past decades, extensive clinical evidence has demonstrated that SRS and SBRT yield outcomes comparable or superior to surgical resection in treating brain metastases, meningiomas, acoustic neuromas, and arteriovenous malformations. This review synthesizes current economic evaluations comparing SRS and SBRT with conventional treatments such as microsurgery and whole-brain radiotherapy (WBRT). From a payer’s perspective, SRS consistently demonstrates lower total costs, reduced hospitalization duration, and fewer complications. For instance, studies from Germany and the Netherlands report significantly higher direct costs for microsurgery—C15,252 and Dfl. 20,072 respectively—compared to C7,920 and Dfl. 14,272 for SRS. Additionally, survival times favor SRS: 18.4 months versus 13.0 months for surgical resection in one German study. The cost per quality-adjusted life year (QALY) is markedly lower with SRS, at $3,762/QALY compared to $8,996/QALY for open surgery, indicating strong cost-effectiveness.
Furthermore, patient-reported outcomes underscore SRS’s advantages. Patients undergoing SRS experience minimal decline in health status across follow-up periods, whereas those treated surgically show significant deterioration in functional scores at 3 months, 1 year, and beyond. In a decision analysis model, SRS plus observation yielded a higher average effectiveness (1.64 life years saved) than SRS plus WBRT (0.6), despite higher upfront costs ($119,000 vs. $74,000), due to improved long-term survival and fewer adverse effects. Even when combined with other therapies, SRS remains cost-saving; RT plus SRS had a median cost of $15,102 versus $22,018 for RT plus surgery, with significantly better cost-effectiveness per QALY gained. These findings highlight that SRS not only improves clinical outcomes but also reduces societal burden by minimizing lost workdays and indirect costs. Overall, SRS offers a clinically effective, patient-friendly, and economically sustainable option for managing brain tumors, particularly in patients who are poor surgical candidates or reside far from specialized centers. Its outpatient nature conserves hospital resources and enables faster return to normal activities, reinforcing its value in modern oncology care.
—
Cost-Effectiveness of SBRT and SRS in Lung Cancer
Stereotactic body radiation therapy (SBRT) has revolutionized the management of medically inoperable non-small cell lung cancer (NSCLC), offering a highly effective alternative to conventional fractionated radiotherapy and surgery. Clinical trials consistently demonstrate that SBRT achieves high local control rates and superior overall survival compared to standard treatments. For example, a 36-month follow-up revealed 71% survival with SBRT versus 42% with 3-dimensional conformal radiotherapy (3DCRT), with significantly lower recurrence rates. Economic analyses confirm these benefits. A study from the United States found that a 4-fraction SBRT course cost between $41,000 and $57,000, while a 35-fraction 3DCRT regimen ranged from $50,000 to $61,000. Despite higher initial treatment costs, SBRT results in lower overall expenses due to fewer sessions, reduced hospital visits, and shorter recovery time.
From a cost-utility standpoint, SBRT outperforms both 3DCRT and radiofrequency ablation (RFA). Markov modeling showed SBRT achieved a mean cost per QALY of $51,133, compared to $48,842 for 3DCRT and $44,648 for RFA. The incremental cost-effectiveness ratio (ICER) for SBRT over 3DCRT was $6,000/QALY, and over RFA it was $14,100/QALY—both within commonly accepted thresholds for cost-effective interventions. Moreover, SBRT patients experienced fewer treatment-related toxicities and required less supportive care, further reducing downstream costs. Although some models were based on retrospective data and limited long-term outcomes, the consistency of findings across multiple studies supports SBRT as a viable, cost-efficient treatment for early-stage NSCLC. Future research should incorporate prospective data, including quality-of-life metrics and real-world resource utilization, to strengthen economic evidence. Nevertheless, SBRT stands as a clinically effective, non-invasive, and economically advantageous option for patients unable to undergo surgery, providing excellent survival outcomes with minimal disruption to daily life.
—
Cost-Effectiveness of SRS and SBRT in Spinal Metastases
Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) have become increasingly recognized as effective treatments for spinal metastases, offering precise tumor targeting with minimal impact on surrounding healthy tissues. While external beam radiation therapy (EBRT) remains a standard approach, recent evidence suggests SBRT provides superior outcomes with potential cost savings over time. A comparative analysis of 100 patients found that although SBRT treatment cost $842,420 compared to $676,309 for 30 Gy in 10 fractions and $499,911 for 20 Gy in 5 fractions, SBRT resulted in fewer acute toxicities and lower retreatment rates. This translates into reduced need for additional interventions, which can drive up costs and affect patient quality of life.
A Markov model evaluating CyberKnife SRS versus EBRT indicated that while SRS cost $11,812 per patient versus $13,745 for EBRT, it conferred an additional 0.08 QALY in net health benefit. This small difference in cost is offset by meaningful improvements in pain control, functional status, and mobility. Furthermore, patients receiving SBRT often avoid prolonged hospital stays and intensive care unit admissions, contributing to lower indirect costs. Studies emphasize that SBRT’s ability to deliver high-dose radiation in just 1–5 sessions reduces the burden on healthcare systems and allows patients to resume normal activities sooner. Despite limited head-to-head economic comparisons, existing data support SBRT as a cost-effective alternative to conventional EBRT, especially for patients with limited life expectancy or those seeking rapid symptom relief.Pyridoxamine 5′-phosphate Protocol Future trials must include standardized quality-of-life assessments and comprehensive cost accounting to fully capture SBRT’s value. Nonetheless, SBRT represents a clinically robust and economically sound strategy for managing spinal metastases, balancing efficacy, safety, and affordability.
—
Cost-Effectiveness of SBRT in Prostate Cancer
Stereotactic body radiation therapy (SBRT) has emerged as a leading treatment option for localized prostate cancer, offering a highly effective, minimally invasive alternative to conventional radiation and surgery.Galectin-1 Protein, Mouse References Recent cost-effectiveness analyses using Markov models indicate that SBRT dominates both intensity-modulated radiation therapy (IMRT) and proton therapy from both payer and societal perspectives.PMID:35101623 In one study, SBRT incurred a cost of $24,873 with 8.11 QALYs, compared to $33,068 and 8.05 QALYs for IMRT, and $69,094 with 8.06 QALYs for proton therapy. From a societal viewpoint, SBRT remained dominant, with total costs of $25,097 versus $35,088 for IMRT and $71,339 for proton therapy.
The economic advantage of SBRT stems from its short treatment course—typically five sessions—reducing patient time off work, travel, and clinic visits. Work-time loss was estimated at only 10 hours for SBRT, compared to 90 hours for IMRT and 100 hours for proton therapy. This efficiency translates into substantial savings in indirect costs related to productivity loss. Moreover, SBRT exhibits low rates of acute and late toxicity, reducing the need for follow-up care and supportive treatments. While long-term data on biochemical disease-free survival remain limited, current models suggest SBRT maintains favorable outcomes without increasing overall treatment burden. The lack of generalizability due to reliance on assumptions about side effects and quality of life highlights the need for prospective, real-world data. Still, SBRT clearly offers a cost-saving, high-value treatment option for men with localized prostate cancer, combining clinical excellence with economic sustainability and patient convenience.
—
Cost-Effectiveness of SBRT in Pancreatic Cancer
Stereotactic body radiation therapy (SBRT) has shown promise in improving survival for patients with locally advanced pancreatic cancer, particularly when combined with chemotherapy. A recent cost-effectiveness analysis evaluated four treatment strategies: gemcitabine alone, gemcitabine plus conventional radiotherapy (RT), gemcitabine plus IMRT, and gemcitabine plus SBRT. The base-case cost of gemcitabine alone was $42,900, rising to $56,700 for gemcitabine plus SBRT. Despite this increase, SBRT extended life expectancy by 0.20 QALY compared to gemcitabine alone, resulting in an ICER of $69,500 per QALY—within acceptable ranges for new oncology therapies.
Notably, gemcitabine plus SBRT dominated both gemcitabine plus RT and gemcitabine plus IMRT in terms of both cost and effectiveness, being more effective and less expensive. In contrast, IMRT was deemed not cost-effective, exceeding typical willingness-to-pay thresholds. The model, however, relied on phase 2 trial data for SBRT and phase 3 data for other arms, introducing uncertainty regarding long-term outcomes. Additionally, assumptions about supportive care costs and quality of life may not reflect real-world variability. Future studies should incorporate prospective data from randomized trials, including detailed measures of toxicity, patient-reported outcomes, and actual resource use. Nonetheless, SBRT offers a compelling combination of clinical benefit and economic value in pancreatic cancer, extending survival with minimal treatment burden. As access to SBRT expands, its role in multimodal therapy will likely grow, making it a cornerstone of cost-effective, high-quality care for this challenging disease.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com